Indus Towers Dividend 2026: Indus Towers, a telecom infrastructure company, has announced a dividend for its shareholders. This is the first dividend announcement by Indus Towers in four years and the first after the share buyback two years ago.

In an exchange filing, Indus Towers said that its board has recommended a final dividend of Rs 14 per share of Rs 10 face value.

Indus Towers Dividend: Statement 

"We are pleased to inform you that the Board of Directors recommended a final dividend of Rs 14 per equity share of face value of Rs 10 each for the financial year ended March 31, 2026,"  Indus Towers said.

Indus Towers Dividend Payment 

The dividend amount of Rs 14 per share is payable, subject to the approval by the shareholders of the company at the upcoming AGM.

The dividend, if approved at the AGM, will be paid to the eligible shareholders within 30 days.

"...subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). The Dividend, if approved, shall be paid within 30 days from the date of shareholders’ approval," Indus Towers added in the filing.

Indus Towers didn't announce the dividend record date along with the dividend amount. Indus Towers dividend record date will be announced in due course and informed to the shareholders via exchanges.

Indus Towers Dividend History

According to the BSE website, Indus Towers had in 2024 announced a share buyback for its shareholders. The company had previously paid a dividend of Rs 22 in 2022. In 2021 and 2022, Indus Towers rewarded its investors by paying them a dividend of Rs 17.82 and Rs 2.30, respectively. 

Indus Towers Q4 Results  FY2026 Highlights

Indus Towers Q4 profit: Rs 1,793 crore

Indus Towers Q4 revenue: Rs 8,101 crore, up 5 per cent YoY

Indus Towers Q4 EBITDA: Rs 4,464 crore, up 1.6 per cent

Indus Towers Q4 EBITDA: 55.1%

Q4 total tower base: 264,514

Indus Towers FY26 profit: Rs 7,145 crore

Indus Towers FY26 consolidated revenue: Rs 32,493 crore

Indus Towers FY26 consolidated EBITDA: Rs 17,976 crore

Hindustan Laboratories IPO: Pharma company receives SEBI observation